Join
Live feed
·
PRReleasevia Quantisnow
Verve Therapeutics Inc. logo

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

ByQuantisnow·Wall Street's wire, on your screen.
VERV· Verve Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VERV (Verve Therapeutics Inc.) and more on Quantisnow.